



Antibodies with two therapeutic domains

The next frontier in combating multiple factorial diseases

The next generation of therapeutics in the post-Ab era is likely to be dominated by dual-domain antibodies. The benefits of such proteins include synergy or additive action, and longer half life. In addition to these advantages, they have the potential to reduce the number of drugs to be taken by a patient. AmProtein has recognized such benefits and is a pioneer in engineering dual-domain protein drugs. We enjoy an IP position that guarantees a freedom to operate, and based on our patents have developed novel dual-domain drugs that have been vindicated in early animal studies. Currently, AmProtein is looking to co-develop its dual-domain protein drug candidates.



Mechanism of Action for IL-18bp-Fc-IL-1ra

Dual-domain drugs are crucial in fighting diseases mediated by multiple factors that no single therapeutic intervention sufficiently treats. It is known that human genes often have multiple domains for a specific function, thus by engineering dual-domain drugs to block two independent pathways, we have developed drugs to combat the following types of disease:

- Autoimmune diseases
- Psoriasis
- Cancer metastasis
- Ischemic heart diseases
- Asthma
- Diabetes



Compared with one-domain drugs, dual-domain drugs may...

- 1) be more efficacious for a specific disease than a single drug.
- 2) have simplified FDA filing than two separate drugs.
- 3) have multiple clinical indications.

AmProtein's patented combinations of dual-domain drug candidates:

- IL-18bp-Fc-IL-1ra
- IL-4R-Fc-IL-1ra
- TNFRI-Fc-IL-1ra
- SymLin-Fc-Leptin
- PYY-Fc-Leptin
- GLP1-Fc-Leptin

Ligand neutralization data



**WO2005/021578,
WO2006/043972, &
WO2007/018619**

We are looking for partners in the US and EU for the co-development of our dual-domain drugs.

Please contact info@amprotein.com for more information.

